We recently compiled a list of The 9 Most Undervalued Pharma Stocks to Buy Right Now. Teva Pharmaceuticals Industries Limited is one of the most undervalued stocks on our list.
TheFly reported on December 9 that Bank of America Securities analyst Jason Gerberry reaffirmed a Buy rating on TEVA and raised his price target to $32.00, reflecting a belief that the stock remains undervalued relative to its track record of revenue improvement and progress in debt reduction.
Also on December 9, 2025, Barclays analyst Glen Santangelo initiated coverage of TEVA with an Overweight rating and a $35.00 price target, indicating increased Wall Street confidence in the Teva brand’s growth drivers and overall strategic progress.
These analyst moves come amid significant developments in Teva Pharmaceuticals Industries Limited’s (NYSE:TEVA) portfolio. On December 9, 2025, TEVA submitted a New Drug Application (NDA) to the US FDA for olanzapine long-acting injectable (LAI) for schizophrenia, based on positive data from the Phase 3 SOLARIS trial supporting its efficacy and safety as a once-monthly subcutaneous formulation. If approved, this asset would expand the company’s branded neuroscience franchise alongside its existing UZEDY (risperidone LAI).
Teva Pharmaceuticals Industries Limited (NYSE:TEVA) is a global leader in the pharmaceutical industry, best known for its strong generics business, complemented by a growing portfolio of specialty and innovative medicines.
While we recognize the risk and potential of TEVA as an investment, our conviction lies in the belief that some AI stocks hold more promise for generating higher returns and doing so in a shorter period of time. If you are looking for an AI stock that is more promising than TEVA and has 10,000% growth potential, check out our report on this. cheapest AI stocks.
READ NEXT: 13 best blue-chip stocks to buy for under $50 and 11 Best Low-Priced Dividend Stocks to Buy According to Analysts.
Disclosure: None.